Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 2.07% is 21% above its 5-year average of 1.71%, around the middle of its 5-year range (-22.28%–30.99%).
28.83% below its 12-month average of 2.91%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 4.26%.
NET PROFIT MARGIN
2.07%
NET PROFIT MARGIN AVG TTM
2.91%
NET PROFIT MARGIN AVG 3Y
3.25%
NET PROFIT MARGIN AVG 5Y
1.71%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-28.83%
CURRENT VS 3Y AVG
-36.28%
CURRENT VS 5Y AVG
+20.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 744 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
GoodRx Holdings, Inc.
Market Cap
$1.15B
Net Profit Margin
2.07%
TTM Avg
2.91%
3Y Avg
3.25%
5Y Avg
1.71%
Market Cap
$1.15B
Net Profit Margin
-287.84%
TTM Avg
-208.97%
3Y Avg
-281.06%
5Y Avg
-321.48%
Market Cap
$1.14B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.13B
Net Profit Margin
-12.40%
TTM Avg
-22.32%
3Y Avg
-24.80%
5Y Avg
-16.46%
Market Cap
$1.13B
Net Profit Margin
-13.51%
TTM Avg
-5.33%
3Y Avg
-11.32%
5Y Avg
-12.84%
Market Cap
$1.13B
Net Profit Margin
10.76%
TTM Avg
17.71%
3Y Avg
18.77%
5Y Avg
14.94%
Market Cap
$1.18B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.10B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.09B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.15B | 2.07% | 2.91% | 3.25% | 1.71% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | -287.84% | -208.97% | -281.06% | -321.48% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | 0.00% | 0.00% | 0.00% | 0.00% |
| OPKO Health, Inc. (OPK)vs › | $1.13B | -12.40% | -22.32% | -24.80% | -16.46% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -13.51% | -5.33% | -11.32% | -12.84% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.76% | 17.71% | 18.77% | 14.94% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.18B | 0.00% | 0.00% | 0.00% | 0.00% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | 0.00% | 0.00% | 0.00% | 0.00% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 26.70% | 26.54% | 25.84% | 21.67% |
Operating Margin
10.3%
Net Profit Margin
2.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 4.26% |
| 2026-03-31 | 0.60% |
| 2025-12-31 | 2.79% |
| 2025-09-30 | 0.57% |
| 2025-06-30 | 6.32% |
| 2025-03-31 | 5.45% |
| 2024-12-31 | 3.39% |
| 2024-09-30 | 6.28% |
| 2024-06-30 | 3.34% |
| 2024-03-31 | -0.51% |
| 2023-12-31 | -13.16% |
| 2023-09-30 | -21.39% |
| 2023-06-30 | 30.99% |
| 2023-03-31 | -1.79% |
| 2022-12-31 | -1.07% |
| 2022-09-30 | -22.28% |
| 2022-06-30 | -0.74% |
| 2022-03-31 | 6.05% |
| 2021-12-31 | -18.72% |
| 2021-09-30 | -9.26% |
| 2021-06-30 | 17.58% |
| 2021-03-31 | 1.04% |
| 2020-12-31 | -194.26% |
| 2020-09-30 | -35.62% |
| 2020-06-30 | 22.17% |
| 2020-03-31 | 20.50% |
| 2019-12-31 | 13.44% |
| 2019-09-30 | 19.28% |
| 2019-06-30 | 21.47% |
| 2019-03-31 | 11.56% |
